Kuros: The Next Attempt at a Rebound

• 

  Christian Ingerl
  Redaktor

The Name Kuros Biosciences may not yet be familiar to every investor. Yet this Swiss medtech company has grown into a remarkable success story in recent years. Headquartered in Schlieren, the company develops synthetic bone substitute materials that are primarily used in spinal and orthopedic procedures. Its flagship product is MagnetOs, which is designed to promote new bone formation and now accounts for a significant portion of the company’s business. In the U.S., MagnetOs has already risen to become the third-largest brand for bone replacement materials in terms of revenue.

On the stock market, however, the company’s operating performance has recently failed to keep pace. From a 52-week high of more than CHF 33, the stock fell to CHF 16.46. Now the stock is attempting to turn things around once again. The pattern is reminiscent of April 2025: Back then, too, this price range proved to be a springboard to significantly higher prices.

Growth remains strong

The first-half results provide a solid foundation. Kuros increased revenue by 45% to USD 92.4 million. Even more important for investors is the growing profitability. Adjusted EBITDA rose by 61% to USD 12.5 million in the first half of the year, and the corresponding margin improved from 12.3% to 13.6%. The bottom line is that the ETH Zurich spin-off posted a profit of USD 4.4 million for the first time in a first half-year. And this despite the fact that the company continues to invest heavily: research and development expenses rose by two-thirds. At the same time, Kuros is broadening its operational base. MagnetOs is no longer growing solely in the traditional spinal business but is also gaining ground in minimally invasive procedures, foot and ankle surgeries, and initial applications in the trauma field. At the same time, the company is expanding its production capacity. The new facility in Alpharetta, U.S., is scheduled to begin production in the second half of 2026, which will not only increase capacity but also reduce supply chain and customs risks.

Next test in mid-October

Kuros will provide new insights as early as October 15 with its third-quarter trading update. Analysts at Kepler Cheuvreux expect another strong growth spurt. Revenue is projected to rise by more than 40% to USD 53.3 million, while the operating margin is expected to improve further to 14.2%. This would bring Kuros very close to its annual target. The company is projecting at least 35% revenue growth and a margin of around 14% for 2026. Thus, the more intriguing question on October 15 may not be whether Kuros will meet its targets, but rather whether management will raise them again.

Analysts are uniformly positive. So far, however, the stock market has only partially reflected these prospects, even though the consensus unanimously rates the stock as a “buy.” The average price target is CHF 32.80, which is about 76% above the current price. If the CHF 16–17 range does indeed prove to be a solid support level once again, this would at least lay the groundwork for a longer-term rebound. A return above the CHF 20 mark would further brighten the technical picture, as the 100-day moving average runs through this level. Above this moving average, the path to the 200-day line – which sits at CHF 22.50 – is relatively clear. Note: The longer-term moving average has already prevented further gains on several occasions this year. However, that wouldn’t be a major concern; up to that point, the upside potential amounts to a whopping 20%.

Investment solutions

Investors willing to take on risk can use the Long Mini-Future MKUCJT from Leonteq. The product has a leverage of 4.24. The financing level is CHF 14.5594, and the stop-loss level is 16.0153 francs. The distance to the knock-out threshold is thus just under 14 percent. Caution: This product reacts disproportionately not only to upward price movements in Kuros stock but also to downward movements.

On the other hand, those who expect prices to move sideways or rise only moderately will find the Barrier Reverse Convertible AHEYTQ – also from Leonteq – a partially protected alternative. The coupon is 10.59% per annum, and the barrier is set at CHF 13.37, well below the current stock price. The maximum return currently stands at 14.28% and 17.26% per annum, respectively. The downside: If the barrier is breached and the stock does not recover sufficiently, losses are possible. On the other hand, the product offers a significant safety buffer; the stock has not reached the barrier level since mid-2024.